Key Players and Strategies in the Post-Herpetic Neuralgia Treatment Market | Fact.MR

The global post-herpetic neuralgia treatment market (帯状疱疹後神経痛治療市場) is expected to grow significantly from an estimated value of US$ 822.4 million in 2024 to US$ 1.38 billion by the end of 2034. This represents a compound annual growth rate (CAGR) of 5.3% during the forecast period of 2024 to 2034. PHN is a form of neuropathic pain that arises from nerve damage caused by the reactivation of the varicella-zoster virus, which also causes shingles or herpes zoster. This condition is more common in areas of the body where there is only one sensory nerve.

Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10057

Market Dynamics:

Postherpetic neuralgia (PHN) is a painful condition that affects nerves and skin, usually occurring after an episode of shingles. The global market for postherpetic neuralgia treatment is primarily driven by the rising prevalence of shingles, especially among the elderly population. According to the Centers for Disease Control and Prevention (CDC), about 1 in 3 people in the United States will develop shingles in their lifetime, with the risk increasing with age.

The market is also influenced by the increasing awareness about postherpetic neuralgia among healthcare professionals and patients, leading to early diagnosis and treatment. Additionally, the development of novel therapeutics and advancements in pain management techniques are expected to drive market growth.

However, the high cost of treatment and the presence of alternative therapies such as acupuncture and herbal medicine may hinder market growth to some extent.

Market Future Outlook:

The postherpetic neuralgia treatment market is expected to witness significant growth in the coming years, driven by factors such as the increasing elderly population, the growing prevalence of shingles, and the introduction of new and effective treatment options. Technological advancements in pain management, such as the development of targeted drug delivery systems, are also expected to fuel market growth.

Moreover, the increasing focus on patient-centric care and the rising demand for personalized medicine are likely to create lucrative opportunities for market players.

Market Insights:

Based on treatment type, the postherpetic neuralgia treatment market (대상포진후 신경통 치료제 시장) can be segmented into medication, nerve blocks, and others. The medication segment is expected to dominate the market, owing to the widespread use of analgesics, anticonvulsants, and antidepressants for pain management in PHN patients.

Geographically, North America is expected to hold a significant share of the global postherpetic neuralgia treatment market, attributed to the high prevalence of shingles in the region and the presence of well-established healthcare infrastructure. Europe is also expected to witness substantial growth, driven by the increasing elderly population and the rising awareness about postherpetic neuralgia.

Key Players:

Pfizer
Arbor Pharma
Assertio Therapeutics
Endo Pharma
Teikoku Pharma
Teva
Mylan
Hengrui Medicine
Acorda Therapeutics,
Purdue Pharma L.P.,
Teikoku Pharma USA, Inc.,
Janssen Pharmaceuticals, Inc.

Competitive Landscape:

Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Endo Pharmaceuticals Inc. collectively hold more than half of the revenue share in the global post-herpetic neuralgia treatment market.

In July 2022, Acasti Pharma announced the initiation of a pharmacokinetic study for GTX-101, its drug candidate for post-herpetic neuralgia treatment. GTX-101 is an innovative formulation of bupivacaine hydrochloride (HCl) designed for topical application using a bio-adhesive, film-forming polymer. This formulation aims to relieve pain associated with post-herpetic neuralgia, a condition caused by nerve damage from the varicella-zoster virus (shingles). The use of bupivacaine hydrochloride (HCl) in the GTX-101 formulation is intended to offer targeted pain relief when applied topically with a bioadhesive film-forming polymer.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=10057

Segmentation of Post Herpetic Neuralgia Treatment Market (Markt für die Behandlung von postherpetischer Neuralgie) Research

By Treatment Type :

Drugs

Patches

Steroid Injectables

By Distribution Channel :

Institutional Sales

Retail Sales

By Region :

North America

Western Europe

Eastern Europe

Latin America

East Asia

South Asia & Pacific

Middle East & Africa

Contact:

US Sales Office

11140 Rockville Pike

Suite 400 Rockville, MD 20852

United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)

Sales Team: sales@factmr.com

About Fact.MR :

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.